Studies of Daiichi Sankyo’s Olmesartan Show “No Clear Evidence” Of CV Risk In Diabetes Patients, FDA Finds
This article was originally published in PharmAsia News
Although data raise “concern of possible increased CV risk” with use of high-dose olmesartan in diabetic patients, FDA concludes that use of the drug in this group can continue.
You may also be interested in...
CDER Deputy Director Bob Temple is a confirmed skeptic of the value of observational trial data to FDA’s regulatory decisions. A recent Medicare study on the bleeding risks associated with Boehringer-Ingelheim’s Pradaxa, however, confirmed an earlier position on the drug by FDA and meets with Temple’s approbation.
Complaint lists host of problems with implementation of the rule that allows states to sponsor programs to import certain prescription drugs from Canada; at least six states have enacted legislation to sponsor these programs.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.